Connect With Us
Subscribe Now
Log In
Home
News
Education
Health
Tech
STEM
Advanced Manufacturing & Logistics
Life Sciences
Ag INnovation
INPower
Videos
Big Wigs
Submit Big Wigs
Events
Innovate Southwest Indiana â Evansville
Innovate West Central Indiana – Terre Haute
Innovate East Central – Muncie
Innovate Northeast Indiana – Fort Wayne
Newsletters
Podcasts
On-Air
TV & Radio Listings
Content Studio
Sponsored Content
Contact
About IIB
Meet the Team
Contact Us
Advertise
Gift Cards
Flagship Stations
Gerry’s Message
Speaking Engagement Request
Search
GO
Connect With Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Coherus Oncology, Inc. - Common Stock
(NQ:
CHRS
)
1.630
-0.075 (-4.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Coherus Oncology, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
US Stocks Edge Higher; Coherus Reports FDA Approval Of UDENYCA ONBODY
↗
December 27, 2023
U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining more than 20 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.08% to 37,575.13 while...
Via
Benzinga
Topics
Stocks
Why Ascent Industries Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
↗
December 27, 2023
Shares of Ascent Industries Co. (NASDAQ: ACNT) rose sharply in pre-market trading as the company reported the sale of the business of Specialty Pipe & Tube for around $55 million in an all-cash deal....
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
December 27, 2023
Via
Benzinga
S&P 500, Nasdaq Set For Wobbly Open As Santa Claus Rally Fades: Analyst Sees Final Trading Sessions As 'Last Great Buying Opportunity'
↗
December 27, 2023
U.S. stocks may face challenges in maintaining their upward momentum on Wednesday, as index futures suggest a flat start. In the absence of significant catalysts, the market might experience a lack of...
Via
Benzinga
Topics
Stocks
What 6 Analyst Ratings Have To Say About Coherus BioSciences
↗
November 28, 2023
Via
Benzinga
Analyst Ratings for Coherus BioSciences
↗
November 08, 2023
Via
Benzinga
Coherus BioSciences And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
↗
December 27, 2023
U.S. stock futures were slightly lower this morning, with the Dow Jones futures falling around 5 points on Wednesday.
Via
Benzinga
Topics
Stocks
Coherus BioSciences, Ascent Industries And 3 Stocks To Watch Heading Into Wednesday
↗
December 27, 2023
With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
December 26, 2023
Via
Benzinga
Coherus BioSciences Stock Is Soaring After-Hours - Here's Why
↗
December 26, 2023
Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher in Tuesday's after-hours session following the company's announcement of the U.S.
Via
Benzinga
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
December 26, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Coherus Biosciences Stock Dropped Today
↗
November 07, 2023
Coherus missed estimates for the third quarter and lowered its full-year outlook.
Via
The Motley Fool
Earnings Scheduled For November 6, 2023
↗
November 06, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via
Benzinga
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
↗
December 24, 2023
These two biotech stocks could be poised for a trend reversal.
Via
The Motley Fool
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
December 11, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces CFO Transition Plans
December 07, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
December 06, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences's Earnings: A Preview
↗
November 03, 2023
Via
Benzinga
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
↗
December 02, 2023
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...
Via
Talk Markets
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical
November 28, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Coherus BioSciences Was Plummeting This Week
↗
November 10, 2023
The company has been punished harshly for a worse-than-expected quarter.
Via
The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
November 07, 2023
Via
Benzinga
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
November 07, 2023
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
Via
Benzinga
Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
↗
November 07, 2023
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
November 07, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
November 07, 2023
It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning.
Via
InvestorPlace
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
November 07, 2023
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
November 06, 2023
Via
Benzinga
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
November 06, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
↗
November 04, 2023
Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have...
Via
Talk Markets
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
